News
AXSM
237.33
-0.25%
-0.59
Weekly Report: what happened at AXSM last week (0615-0619)?
Weekly Report · 3d ago
Axsome Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 06/17 14:03
TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300
Benzinga · 06/17 13:53
Axsome Therapeutics price target raised to $300 from $275 at TD Cowen
TipRanks · 06/17 12:26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Guardian Pharmacy Services, Inc. Class A (GRDN) and Alto Neuroscience, Inc. (ANRO)
TipRanks · 06/17 11:31
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Axsome Therapeutics (AXSM)
TipRanks · 06/17 09:50
Axsome to Present New Sleep Disorder Data at SLEEP 2026, To Highlight AXS-12 and Solriamfetol Data for Narcolepsy and OSA
Benzinga · 06/15 11:10
Axsome presents new Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
PUBT · 06/15 11:01
Weekly Report: what happened at AXSM last week (0608-0612)?
Weekly Report · 06/15 10:38
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Doximity (DOCS) and Axsome Therapeutics (AXSM)
TipRanks · 06/11 09:41
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
Reuters · 06/11 07:59
AXSOME THERAPEUTICS INC <AXSM.O>: JEFFERIES RAISES TARGET PRICE TO $380 FROM $275
Reuters · 06/11 04:03
Axsome Shareholders Back Directors, Auditor and Executive Pay
TipRanks · 06/09 22:50
Axsome adopts new executive severance and control plan
TipRanks · 06/09 22:49
Axsome adopts executive severance, change-in-control plan effective June 5, 2026
PUBT · 06/09 21:21
Axsome Therapeutics shareholders elect Saad, Mahony as Class II directors
PUBT · 06/09 21:20
Axsome CFO Nick Pizzie sells 33,000 shares for $7.92 million
PUBT · 06/09 21:17
Weekly Report: what happened at AXSM last week (0601-0605)?
Weekly Report · 06/08 10:32
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
Barchart · 06/05 23:02
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Charles River Labs (CRL) and Axsome Therapeutics (AXSM)
TipRanks · 06/04 12:40
More
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.